HR Execs on the Move

CardiaLen

www.cardialen.com

 
Established in 2008, Cardialen, Inc., set out to develop an implantable defibrillator using low-electrical energy to restore normal heart rhythm and potentially avoid the negative side-effects of current therapies.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.cardialen.com
  • 212 Third Ave. N. Suite 352
    Minneapolis, MN USA 55401
  • Phone: 612.208.1260

Executives

Name Title Contact Details

Similar Companies

aTyr Pharma

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the Neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases.

Encore Rehabilitation

Encore Rehabilitation is a Berkley, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Standards Testing Laboratory

STL now operates the world's largest independent dynamic testing facility for tires, wheels and related automotive components, providing the rubber and automotive industries with dynamic laboratory testing, static and physical testing, fleet testing,

CellGenix

CellGenix is a leading global supplier of high quality raw and ancillary materials for the expanding market of cell and gene therapy and regenerative medicine. CellGenix develops, manufactures and markets human cytokines, growth factors, and other recombinant cell culture components in preclinical and GMP quality as well as proprietary serum-free media for further manufacturing of ATMPs. As a former ATMP developer and manufacturer, in more than two decades CellGenix gained in-depth cell processing knowledge and superior regulatory expertise. With this unique background, CellGenix understands the high requirements their customers are facing during product development and the regulatory approval process. To meet the increasing demand of GMP quality raw materials for ATMP manufacturing CellGenix has recently expanded manufacturing capacity, built additional R&D and QC laboratories, and warehouse space. The upgrade also introduced state-of-the-art, automated, large-scale capacities for recombinant protein products in the existing GMP facilities. CellGenix is headquartered in Freiburg, Germany and operates a subsidiary near Boston in Portsmouth, USA.

ISI Interscience

ISI Interscience is a Troy, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.